FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and concerns improvement of lipid profile in patients with ischemic heart disease. For this purpose, the standard therapy is accompanied by the sequential administration within 28 days of the non-resorbable antibiotic rifaximin for 7 days, then the multi-steril probiotic Florasana D for 21 days.
EFFECT: method provides effective correction of the lipid profile, namely low level of lipoproteins of very low density in the given group of patients, due to normalization of intestinal microbiota.
1 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING ISCHEMIC HEART DISEASE | 2010 |
|
RU2438665C1 |
SPECIES FOR TREATMENT OF PATIENTS WITH VASCULAR DISEASES AND DISTURBANCE OF LIPID METABOLISM | 2002 |
|
RU2227040C1 |
METHOD OF LIPID METABOLIC DISORDER CORRECTION | 2007 |
|
RU2337696C1 |
METHOD FOR DISLIPIDEMIA PREVENTION | 2016 |
|
RU2621152C1 |
METHOD FOR PREDICTING CLINICAL BEHAVIOR OF CARDIAC ISCHEMIA DISEASE | 2001 |
|
RU2228534C2 |
METHOD FOR CORRECTION OF LIPOPEROXIDATION ACCOMPANYING HYPOLIPIDEMIC THERAPY OF PATIENTS WITH METABOLIC SYNDROME | 2011 |
|
RU2458687C1 |
METHOD FOR ASSESSING PROGRESSION OF ATHEROGENICITY IN ISCHEMIC HEART DISEASE | 2013 |
|
RU2521322C1 |
METHOD OF PREVENTING LIPID EXCHANGE DISORDERS | 2009 |
|
RU2423123C1 |
METHOD FOR DIAGNOSING AND PREDICTING CARDIAC ISCHEMIA DISEASE | 1999 |
|
RU2173853C2 |
HYPOLIPIDEMIC PHYTOAGENT | 2013 |
|
RU2553309C2 |
Authors
Dates
2019-12-12—Published
2018-08-01—Filed